Precigen Inc (PGEN)

$4.38 -0.13 (-2.88%)
Market Cap 1.60B
Revenue (ttm) 3.93M
Net Income (ttm) -126.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,212.21%
Debt to Equity Ratio 2.22
Volume 6,025,800
Avg Vol 4,573,438
Day's Range N/A - N/A
Shares Out 353.83M
Stochastic %K 19%
Beta 1.07
Analysts Sell
Price Target $8.50

Company Profile

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine an...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 556 9900
Address:
20374 Seneca Meadows Parkway, Germantown, United States
OtisHisle631
OtisHisle631 Feb. 21 at 5:31 AM
$PGEN Precigen develops gene and cell therapies. Clinical execution drives valuation. Funding runway is a key risk.
1 · Reply
dsup
dsup Feb. 21 at 1:58 AM
$PGEN march 19
1 · Reply
fredster45
fredster45 Feb. 20 at 9:17 PM
$PGEN bought 6000 shares in after hours at 4.31.
0 · Reply
blue_horseshoe_9P
blue_horseshoe_9P Feb. 20 at 8:10 PM
$PGEN Hit a high of $5.42 this week and dropped like a rock. WTF man…ruined my weekend.
1 · Reply
M22
M22 Feb. 20 at 8:01 PM
$PGEN no worries 👍💎🤲
0 · Reply
SlyCooper007
SlyCooper007 Feb. 20 at 6:27 PM
$PGEN
0 · Reply
chungana
chungana Feb. 20 at 5:55 PM
$PGEN Wonder why the price is pretty much pinned around $4.50…hmmm? 🤔
0 · Reply
chungana
chungana Feb. 20 at 4:42 PM
$PGEN “If Wall Street were a casino, institutions would be the house—setting the odds, adjusting the game, and ensuring they come out ahead regardless of market conditions. Retail traders, on the other hand, are like eager gamblers walking into a Vegas casino, lured by the potential of riches but often leaving with empty pockets. Institutions don’t leave their success to chance; they leverage exclusive access to tools and markets that average investors simply cannot reach. Their use of dark pools—private exchanges where large orders can be executed without impacting public market prices—allows them to strategically accumulate or offload positions without alerting the broader market.” https://sites.lsa.umich.edu/mje/2025/04/03/the-house-always-wins-how-institutions-use-options-to-control-the-market/
2 · Reply
SlyCooper007
SlyCooper007 Feb. 20 at 4:17 PM
$PGEN
0 · Reply
Stocktwits019475
Stocktwits019475 Feb. 20 at 4:04 PM
$PGEN Technicals are very strong with this one. On an uptrend. I’m in
0 · Reply
Latest News on PGEN
Precigen: PAPZIMEOS Is Delivering For This Under-The-Radar Biotech

Feb 11, 2026, 9:34 AM EST - 10 days ago

Precigen: PAPZIMEOS Is Delivering For This Under-The-Radar Biotech

New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis

Jan 20, 2026, 8:05 AM EST - 4 weeks ago

New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis

Precigen, Inc. (PGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 15, 2026, 12:55 PM EST - 5 weeks ago

Precigen, Inc. (PGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:00 AM EST - 5 weeks ago

Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference

Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:05 PM EST - 6 weeks ago

Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference

Precigen Is Still A Buy After The Papzimeos Rally

Nov 25, 2025, 6:51 AM EST - 3 months ago

Precigen Is Still A Buy After The Papzimeos Rally

Precigen, Inc. (PGEN) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 10:51 PM EST - 3 months ago

Precigen, Inc. (PGEN) Q3 2025 Earnings Call Transcript

Precigen Reports Third Quarter 2025 Financial Results and Business Updates

Nov 13, 2025, 4:05 PM EST - 3 months ago

Precigen Reports Third Quarter 2025 Financial Results and Business Updates

Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13

Nov 6, 2025, 4:30 PM EST - 3 months ago

Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

Oct 13, 2025, 7:00 AM EDT - 4 months ago

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

Precigen Announces Up to $125 Million Non-Dilutive Financing

Sep 3, 2025, 7:00 AM EDT - 6 months ago

Precigen Announces Up to $125 Million Non-Dilutive Financing

Precigen, Inc. - Special Call

Sep 2, 2025, 1:55 PM EDT - 6 months ago

Precigen, Inc. - Special Call

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

Aug 25, 2025, 8:05 AM EDT - 6 months ago

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

Undercovered Dozen: Precigen, ONEOK, Bitmine And More

Aug 22, 2025, 10:43 AM EDT - 6 months ago

Undercovered Dozen: Precigen, ONEOK, Bitmine And More

BMNR OKE

Precigen: This Billion-Dollar Approval Is Still Undervalued

Aug 15, 2025, 3:15 PM EDT - 6 months ago

Precigen: This Billion-Dollar Approval Is Still Undervalued

Why Is Precigen Stock Surging On Friday?

Aug 15, 2025, 9:48 AM EDT - 6 months ago

Why Is Precigen Stock Surging On Friday?

US FDA approves Precigen's immunotherapy for rare respiratory disease

Aug 15, 2025, 7:18 AM EDT - 6 months ago

US FDA approves Precigen's immunotherapy for rare respiratory disease

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Aug 15, 2025, 7:00 AM EDT - 6 months ago

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen: August Is Pivotal For This Biotech Innovator

Jul 7, 2025, 5:58 PM EDT - 8 months ago

Precigen: August Is Pivotal For This Biotech Innovator

Precigen Reports First Quarter 2025 Financial Results and Business Updates

May 14, 2025, 4:05 PM EDT - 10 months ago

Precigen Reports First Quarter 2025 Financial Results and Business Updates

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

Apr 16, 2025, 8:05 AM EDT - 11 months ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 7:47 PM EDT - 1 year ago

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

Precigen Reports Full Year 2024 Financial Results and Business Updates

Mar 19, 2025, 4:05 PM EDT - 1 year ago

Precigen Reports Full Year 2024 Financial Results and Business Updates

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

Mar 13, 2025, 8:05 AM EDT - 1 year ago

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

Feb 28, 2025, 8:56 AM EST - 1 year ago

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Feb 25, 2025, 8:05 AM EST - 1 year ago

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 7:00 AM EST - 1 year ago

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:30 AM EST - 1 year ago

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Dec 30, 2024, 7:00 AM EST - 1 year ago

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Dec 27, 2024, 9:00 AM EST - 1 year ago

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Nov 14, 2024, 4:30 PM EST - 1 year ago

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Precigen to Participate in the Stifel 2024 Healthcare Conference

Nov 12, 2024, 4:05 PM EST - 1 year ago

Precigen to Participate in the Stifel 2024 Healthcare Conference

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Sep 16, 2024, 4:30 PM EDT - 1 year ago

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session

Aug 15, 2024, 8:11 AM EDT - 1 year ago

Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session

GGR TITN

Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 7:03 PM EDT - 1 year ago

Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

Aug 7, 2024, 9:30 PM EDT - 1 year ago

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

Precigen Announces Proposed $30 Million Public Offering of Common Stock

Aug 6, 2024, 4:04 PM EDT - 1 year ago

Precigen Announces Proposed $30 Million Public Offering of Common Stock

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

Jul 23, 2024, 8:01 AM EDT - 1 year ago

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

Jun 3, 2024, 9:30 AM EDT - 1 year ago

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

May 23, 2024, 5:00 PM EDT - 1 year ago

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

Precigen Reports First Quarter 2024 Financial Results and Business Updates

May 14, 2024, 4:05 PM EDT - 1 year ago

Precigen Reports First Quarter 2024 Financial Results and Business Updates

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

May 8, 2024, 4:05 PM EDT - 1 year ago

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

Apr 24, 2024, 10:20 AM EDT - 1 year ago

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

Actym Therapeutics Appoints Thomas Smart as CEO

Apr 24, 2024, 9:00 AM EDT - 1 year ago

Actym Therapeutics Appoints Thomas Smart as CEO

ANAB XOMA

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 8:49 PM EDT - 2 years ago

Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript

Precigen Reports Full Year 2023 Financial Results and Business Updates

Mar 19, 2024, 4:05 PM EDT - 2 years ago

Precigen Reports Full Year 2023 Financial Results and Business Updates

OtisHisle631
OtisHisle631 Feb. 21 at 5:31 AM
$PGEN Precigen develops gene and cell therapies. Clinical execution drives valuation. Funding runway is a key risk.
1 · Reply
dsup
dsup Feb. 21 at 1:58 AM
$PGEN march 19
1 · Reply
fredster45
fredster45 Feb. 20 at 9:17 PM
$PGEN bought 6000 shares in after hours at 4.31.
0 · Reply
blue_horseshoe_9P
blue_horseshoe_9P Feb. 20 at 8:10 PM
$PGEN Hit a high of $5.42 this week and dropped like a rock. WTF man…ruined my weekend.
1 · Reply
M22
M22 Feb. 20 at 8:01 PM
$PGEN no worries 👍💎🤲
0 · Reply
SlyCooper007
SlyCooper007 Feb. 20 at 6:27 PM
$PGEN
0 · Reply
chungana
chungana Feb. 20 at 5:55 PM
$PGEN Wonder why the price is pretty much pinned around $4.50…hmmm? 🤔
0 · Reply
chungana
chungana Feb. 20 at 4:42 PM
$PGEN “If Wall Street were a casino, institutions would be the house—setting the odds, adjusting the game, and ensuring they come out ahead regardless of market conditions. Retail traders, on the other hand, are like eager gamblers walking into a Vegas casino, lured by the potential of riches but often leaving with empty pockets. Institutions don’t leave their success to chance; they leverage exclusive access to tools and markets that average investors simply cannot reach. Their use of dark pools—private exchanges where large orders can be executed without impacting public market prices—allows them to strategically accumulate or offload positions without alerting the broader market.” https://sites.lsa.umich.edu/mje/2025/04/03/the-house-always-wins-how-institutions-use-options-to-control-the-market/
2 · Reply
SlyCooper007
SlyCooper007 Feb. 20 at 4:17 PM
$PGEN
0 · Reply
Stocktwits019475
Stocktwits019475 Feb. 20 at 4:04 PM
$PGEN Technicals are very strong with this one. On an uptrend. I’m in
0 · Reply
chungana
chungana Feb. 20 at 2:17 PM
$PGEN Holding shares through next CC…Looking for numbers on patients treated, as well as potential patients in the overall portals. If patients currently being treated is over 100, that would be solid, imho. Portal patients need to be over 500 and climbing. Good forward guidance on this year’s revs—$150 million+ (and next year’s revs—$300 million+) would go a long way to lifting share price next month.
0 · Reply
dsup
dsup Feb. 20 at 3:39 AM
$PGEN new river pharma, company that created vyvance the ADHD drug, was founded by RJ kirk in the 90’s. they went on to sell to shire for 2.6 billion and kirk made a billion alone from that deal. the drug went on to be massive and he left billions on the table because he didn’t want to take the risk of commercializing and whatnot himself. i feel like he is not going to let that happen again this time around 🤷
1 · Reply
chungana
chungana Feb. 20 at 2:24 AM
$PGEN
1 · Reply
JackFrost25
JackFrost25 Feb. 20 at 1:59 AM
$PGEN There is an outstanding interest of 700 contracts for all strike prices combined on Friday 20 February. That is a very low number and unlikely to affect stock price. April, July, October and January are the months with the largest outstanding interest.
1 · Reply
chungana
chungana Feb. 20 at 1:21 AM
$PGEN “Options writers (sellers) aim for the underlying stock to stay below the strike price so the call options they sold expire worthless, allowing them to keep the premium as profit. While writers may hold stock to hedge (covered calls), selling shares specifically to manipulate prices down is generally illegal market manipulation, though high-volume option hedging can influence prices.” Key phrase: ”generally illegal market manipulation.” Today’s market is incredibly corrupt.
0 · Reply
zackplanet42
zackplanet42 Feb. 19 at 9:11 PM
$PGEN Max pain sitting right at $4 for tomorrow Big fish are going to push the price that direction, one way or another. Take advantage if you have the means, otherwise just ride it out with the rest of us. Look out for March expiry. Earnings report timed for the day before. Expect explosive movement. Should be fun
0 · Reply
chungana
chungana Feb. 19 at 6:59 PM
$PGEN This price manipulation is likely being done by the options writers to save their asses. They know SEC doesn’t police the market (especially if they get nice kickbacks from options writers). So, price was just near $5.50 a couple days ago; and, ”miraculously,” it is now down 20% in two days below $4.50. Check all the calls at $4.50, $5, and $5.50…Writers going to make sure they all expire worthless tomorrow.
1 · Reply
erkdg
erkdg Feb. 19 at 6:37 PM
$PGEN 4th wave in two months. Loaded today the part i sold at 5.3. When it tested 4s investors loaded based on fillings. Each wave seems bottomed higher. So looking good for an other swing before the earnings.
0 · Reply
longshort777
longshort777 Feb. 19 at 6:28 PM
$PGEN guarantee this flys Friday or Monday. So manipulated
2 · Reply
bullwink
bullwink Feb. 19 at 6:02 PM
$PGEN Does anyone have any phukking idea what is going on? From 5.47 to 4.35 in 2 days?
2 · Reply
SlyCooper007
SlyCooper007 Feb. 19 at 5:59 PM
$PGEN Another 10% drop. Following the same pattern as yesterday.
0 · Reply
CP06Trades
CP06Trades Feb. 19 at 5:51 PM
$PGEN Loading up in the 4.20's
0 · Reply